Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mycobacterium tuberculosis antigen
- Development stage
- Unknown
- Lead developer
- Anbozhi Lian
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
EM (Mycobacterium tuberculosis antigen) is an investigational recombinant protein-based diagnostic skin-test antigen developed by Anbozhi Lian (Suzhou) Biotechnology. It is designed for the auxiliary diagnosis of tuberculosis (TB) and the detection of latent Mycobacterium tuberculosis infection (LTBI). Administered via intradermal injection, the antigen triggers a delayed-type hypersensitivity (DTH) response in individuals whose immune systems have been sensitized to M. tuberculosis. This response, typically measured by skin induration, allows for the identification of infected individuals. As a Mycobacterium tuberculosis antigen-based skin test (TBST), EM aims to provide higher specificity than the traditional tuberculin skin test (TST) by utilizing specific antigens that do not cross-react with the BCG vaccine. It is currently in Phase IIa clinical development in China.
- Other names
- EM皮肤试验用结核分枝杆菌抗原
02
Targets
MHC I (MHC class I})
Beyond the preview
Go deeper on mycobacterium tuberculosis antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mycobacterium tuberculosis antigen.